Regeneron Bolsters I-O Portfolio with US$250 M Checkmate Acquisition

By Lucy Haggerty

Pharma Deals Review: Vol 2022 Issue 4 (Table of Contents)

Published: 21 Apr-2022

DOI: 10.3833/pdr.v2022.i4.2686     ISSN: 1756-7874

Section: Mergers & Acquisitions

Fulltext:

Abstract

In an attempt to expand its immuno-oncology portfolio, Regeneron has agreed to acquire Checkmate Pharmaceuticals for US$10...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details